Psychiatric symptoms such as hallucination may indicate specific molecular pathologies of frontotemporal lobar degeneration (FTLD); the authors suggest neuropsychiatric symptoms should be routinely examined in patients with frontotemporal dementia (FTD).
Why this matters
FTD is a clinical diagnosis which covers a group of diverse neurodegenerative disorders, including behavioral variant of FTD and primary progressive aphasia. Diagnosing FTD is challenging due to the varied clinical presentations and a lack of biomarkers.
FTLD is a pathological diagnosis based on neuroanatomical imaging and the presence of molecular aggregates like TDP-43, tau and FUS.
Although some patients with FTD also have FTLD pathology, other patients do not.
Finding relationships between the clinical presentation and underling molecular pathology of FTD and FTLD would improve understanding of these conditions.